On July 31, 2022, Szeto, Andy H.; Bucci, Tyler; Deal, Allison; Zhu, Anqi; Ahmad, Majd; Cass, Amanda S.; Sketch, Margaret R.; Kemper, Ryan; Zeidner, Joshua F.; Foster, Matthew C.; Muluneh, Benyam; Crona, Daniel J. published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia. And the article contained the following:
Tyrosine kinase inhibitors (TKIs) are the front-line therapy for chronic myeloid leukemia (CML), where phase 3 clin. trials have demonstrated their safety and efficacy. However, trial patients may not be representative of real-world patients (RWPs). To evaluate RWP clin. factors associated with effectiveness and safety in CML patients treated with TKIs. Patients with CML treated with at least 30 days of imatinib, dasatinib, nilotinib, or bosutinib between 2014 and 2018 were included. Patients were stratified into categories based on the number of factors that would have precluded enrollment into pivotal TKI phase 3 trials (0, 1, ≥2). End points included complete hematol. response (CHR), early mol. response (EMR), major mol. response (MMR), adverse event (AE)-induced dose decreases, treatment interruptions, and treatment discontinuations. Final analyses included 174 patients. Patients with ≥2 factors had a higher risk of dose decreases (relative risk = 1.54; 95% CI = 1.02-2.34; P = 0.02) and a shorter time to dose decrease (hazard ratio = 2.43; 95% CI = 1.23-4.97; P = 0.006) compared with patients with 0 factors. Significant differences were observed in CHR at 1 mo and MMR at 3 mo between patients with 0 and ≥2 factors (P = 0.03 and P = 0.04, resp.). Approx. 60% of our RWPs would have been excluded from the pivotal phase 3 TKI trials. These data suggest that RWPs require more precise dosing to achieve CML clin. milestones and to mitigate AEs, but findings should be validated prospectively. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
The Article related to imatinib dasatinib anticancer agent chronic myeloid leukemia adult, adverse drug events, bosutinib, chronic myeloid leukemia, dasatinib, effectiveness, imatinib, nilotinib, real-world patients, tyrosine kinase inhibitors and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics